AR072544A1 - Metodo anticonceptivo mejorado. sistema de suministro. uso. progestageno - Google Patents
Metodo anticonceptivo mejorado. sistema de suministro. uso. progestagenoInfo
- Publication number
- AR072544A1 AR072544A1 ARP090102452A ARP090102452A AR072544A1 AR 072544 A1 AR072544 A1 AR 072544A1 AR P090102452 A ARP090102452 A AR P090102452A AR P090102452 A ARP090102452 A AR P090102452A AR 072544 A1 AR072544 A1 AR 072544A1
- Authority
- AR
- Argentina
- Prior art keywords
- progestogen
- delivery system
- suppress abnormal
- contraception
- drug
- Prior art date
Links
- 239000000583 progesterone congener Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 title 1
- 230000001380 anti-conceptive effect Effects 0.000 title 1
- 239000003433 contraceptive agent Substances 0.000 title 1
- 206010046788 Uterine haemorrhage Diseases 0.000 abstract 4
- 230000002159 abnormal effect Effects 0.000 abstract 4
- 230000001788 irregular Effects 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 230000000757 progestagenic effect Effects 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 230000002035 prolonged effect Effects 0.000 abstract 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 abstract 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 abstract 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 abstract 1
- 201000000736 Amenorrhea Diseases 0.000 abstract 1
- 206010001928 Amenorrhoea Diseases 0.000 abstract 1
- 231100000540 amenorrhea Toxicity 0.000 abstract 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 abstract 1
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 abstract 1
- 229960000766 danazol Drugs 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 229960004400 levonorgestrel Drugs 0.000 abstract 1
- 229960003464 mefenamic acid Drugs 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 abstract 1
- 229960000401 tranexamic acid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Communication Control (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08397516A EP2140860A1 (en) | 2008-07-03 | 2008-07-03 | An improved method of contraception |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072544A1 true AR072544A1 (es) | 2010-09-08 |
Family
ID=40020198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102452A AR072544A1 (es) | 2008-07-03 | 2009-07-01 | Metodo anticonceptivo mejorado. sistema de suministro. uso. progestageno |
Country Status (23)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20080524A0 (fi) | 2008-09-17 | 2008-09-17 | Bayer Schering Pharma Oy | Insertteri |
| FI20080523A0 (fi) | 2008-09-17 | 2008-09-17 | Bayer Schering Pharma Oy | Insertteri |
| WO2010031902A1 (en) | 2008-09-17 | 2010-03-25 | Bayer Schering Pharma Oy | An inserter |
| WO2012121811A1 (en) * | 2011-03-04 | 2012-09-13 | Arstat, Inc. | Treatment of excessive menstrual blood loss by intravaginal administration of low doses of antifibronlytic or hemostatic agent |
| US10028858B2 (en) | 2011-07-11 | 2018-07-24 | Medicines360 | Intrauterine systems, IUD insertion devices, and related methods and kits therefor |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| PL2782584T3 (pl) | 2011-11-23 | 2021-12-13 | Therapeuticsmd, Inc. | Naturalne skojarzone hormonalne formulacje i terapie zastępcze |
| AR089765A1 (es) | 2012-01-23 | 2014-09-17 | Bayer Oy | Un sistema para el suministro de un farmaco |
| TW201350122A (zh) * | 2012-04-23 | 2013-12-16 | Bayer Pharma AG | １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途 |
| USD718435S1 (en) | 2012-05-30 | 2014-11-25 | Medicines360 | Intrauterine insertion device |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| SE539540C2 (sv) | 2013-09-12 | 2017-10-10 | Qpharma Ab | Ett läkemedelsavgivningssystem för en eller flera aktiva beståndsdelar |
| JP2016539088A (ja) * | 2013-10-18 | 2016-12-15 | バイエル・オサケユキテュアＢａｙｅｒ Ｏｙ | 子宮内送達システム |
| MX2016014281A (es) | 2014-05-22 | 2017-02-22 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo de combinación de hormonas naturales. |
| WO2015189853A1 (en) | 2014-06-13 | 2015-12-17 | Meril Endo Surgery Private Limited | An intrauterine device |
| TWI730948B (zh) * | 2014-12-08 | 2021-06-21 | 芬蘭商拜耳股份有限公司 | 新穎的熱塑性聚胺甲酸酯，彼等材料於製造子宮內系統之ｔ-框架之用途及由此等材料製成之ｔ-框架 |
| HUE046267T2 (hu) * | 2015-01-21 | 2020-02-28 | Bayer Oy | Nem szteroid gyulladáscsökkentõ (NSAID) és progesztogén vegyületet tartalmazó gyógyszerbeviteli rendszer és elõállítási eljárások |
| US20180140640A1 (en) | 2015-04-22 | 2018-05-24 | Cadens Beheer B.V. | Improved contraceptive methods and compositions and devices for use therein |
| EP3294300B1 (en) | 2015-05-13 | 2024-12-18 | Bayer Oy | Long acting drug delivery device in form of an implant or iud comprising levonorgestrel and ethinylestradiol |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017108676A1 (en) * | 2015-12-21 | 2017-06-29 | Bayer Oy | Method for manufacturing a drug delivery device and a drug delivery device manufactured according to the method |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| GB2555373A (en) * | 2016-08-23 | 2018-05-02 | Reproductive Medicine And Gynaecology Associates Ltd | Implant |
| AU201617347S (en) * | 2016-12-23 | 2017-01-23 | Jurox Pty Ltd | intravaginal device |
| PE20211195A1 (es) * | 2017-09-27 | 2021-07-01 | Bayer Oy | Un metodo para modificar la liberacion de un agente terapeuticamente activo de una matriz elastomerica |
| CN111770750B (zh) | 2017-12-22 | 2024-05-10 | 阿利拉生物科技有限公司 | 痛经有关的疼痛和/或疼痛相关症状的治疗 |
| US20200268932A1 (en) * | 2019-02-22 | 2020-08-27 | Arsenal Aaa, Llc. | Crosslinkable polymer compositions |
| WO2020172418A1 (en) * | 2019-02-22 | 2020-08-27 | Elkem Silicones USA Corp. | Drug delivery silicone compositon to improve active ingredient elution |
| KR102260999B1 (ko) | 2019-03-27 | 2021-06-04 | (주)엠케어코리아 | 난소암 검사용 임플란트 및 이를 포함하는 검사킷 및 이를 이용한 난소암 검사방법 |
| US20220233469A1 (en) | 2019-05-31 | 2022-07-28 | Alyra Biotech Pty Ltd | Methods, compositions and devices for treating neuroinflammatory conditions |
| CN110215447A (zh) * | 2019-06-14 | 2019-09-10 | 上海市计划生育科学研究所 | 甲芬那酸在避孕药物中的应用及其制备的杀精避孕药物 |
| WO2021102220A1 (en) | 2019-11-21 | 2021-05-27 | Coopersurgical, Inc. | Packaging systems for implantable devices and related methods |
| CN116807727B (zh) * | 2023-08-29 | 2023-11-21 | 上海宇度医学科技股份有限公司 | 一种妇产科医师用临床取环器 |
| WO2025106820A1 (en) * | 2023-11-16 | 2025-05-22 | University Of South Florida | Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3880991A (en) * | 1969-03-24 | 1975-04-29 | Brook David E | Polymeric article for dispensing drugs |
| US4188951A (en) | 1972-08-17 | 1980-02-19 | Alza Corporation | Intrauterine system embracing selected copolymeric membranes for administering beneficial agent |
| US4495934A (en) | 1978-07-25 | 1985-01-29 | Shaw Jr Seth T | IUD Arrangement |
| US4284074A (en) * | 1978-07-26 | 1981-08-18 | Shaw Jr Seth T | IUD Arrangement |
| AU538963B2 (en) | 1979-07-09 | 1984-09-06 | Seth Thomas Shaw Jr. | Drug for use with an iud |
| FR2539027B1 (fr) | 1983-01-07 | 1987-03-06 | Levrier Marc | Systeme endo-uterin contraceptif et therapeutique associant cuivre, argent, hormone naturelle et acide iso amino caproique |
| NL8603216A (nl) * | 1986-12-17 | 1988-07-18 | Kurz Karl Heinz | Inrichting om in de uterus te plaatsen. |
| JP2590358B2 (ja) * | 1988-03-01 | 1997-03-12 | 正雄 五十嵐 | 子宮内膜症治療用の子宮内又は膣内投与製剤 |
| FR2695826B1 (fr) * | 1992-09-21 | 1995-01-06 | Theramex | Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention. |
| FI94947C (fi) | 1994-04-05 | 1995-11-27 | Maillefer Nokia Holding | Sovitelma lankamaisia tuotteita puolaavan koneen yhteydessä |
| FI97944C (fi) | 1994-07-05 | 1997-03-25 | Leiras Oy | Vaikuttavaa ainetta luovuttava laite |
| FI97947C (fi) | 1994-09-27 | 1997-03-25 | Leiras Oy | Menetelmä lääkepreparaatin valmistamiseksi |
| WO1998005293A2 (en) * | 1996-08-02 | 1998-02-12 | The Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
| AU4808997A (en) * | 1996-09-30 | 1998-04-24 | Brigham And Women's Hospital | Methods and compounds for treatment of abnormal uterine bleeding |
| FI103051B1 (fi) | 1997-08-22 | 1999-04-15 | Leiras Oy | Uusia blokkikopolymeerejä ja niiden valmistus |
| FI107339B (fi) | 1998-06-30 | 2001-07-13 | Leiras Oy | Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi |
| US6056976A (en) | 1998-11-12 | 2000-05-02 | Leiras Oy | Elastomer, its preparation and use |
| DE10045380A1 (de) * | 2000-09-14 | 2002-04-04 | Schering Ag | Verfahren zur Kontrazeption und dessen Darreichungsform |
| WO2002038159A1 (fr) * | 2000-11-10 | 2002-05-16 | Mitsubishi Pharma Corporation | Medicaments pour l'hyperplasie endometriale |
| CA2457979A1 (en) * | 2001-08-31 | 2003-03-06 | Schering Oy | A delivery system |
| JP2003221338A (ja) * | 2002-01-29 | 2003-08-05 | Masao Igarashi | 子宮腺筋症治療製剤 |
| US7833545B2 (en) * | 2003-04-29 | 2010-11-16 | The General Hospital Corporation | Methods and devices for the sustained release of multiple drugs |
| WO2006028431A1 (en) | 2003-05-21 | 2006-03-16 | Impres Medical, Inc. | Intrauterine implant and methods of use |
| GB0320238D0 (en) * | 2003-08-29 | 2003-10-01 | Medical Res Council | Treatment of disease |
| FI123188B (fi) * | 2005-04-05 | 2012-12-14 | Bayer Oy | Ultraäänellä havaittavissa oleva kohdunsisäinen järjestelmä |
| US7862552B2 (en) * | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
| CN100441156C (zh) * | 2006-09-30 | 2008-12-10 | 华中科技大学 | 一种复合材料宫内节育器 |
-
2008
- 2008-07-03 EP EP08397516A patent/EP2140860A1/en not_active Withdrawn
-
2009
- 2009-06-11 TW TW098119470A patent/TW201002288A/zh unknown
- 2009-06-11 TW TW104133303A patent/TWI602556B/zh not_active IP Right Cessation
- 2009-06-26 CL CL2009001490A patent/CL2009001490A1/es unknown
- 2009-07-01 CN CN2009801259913A patent/CN102088954A/zh active Pending
- 2009-07-01 WO PCT/FI2009/050598 patent/WO2010000943A1/en not_active Ceased
- 2009-07-01 SM SM20180295T patent/SMT201800295T1/it unknown
- 2009-07-01 PT PT141933929T patent/PT2905014T/pt unknown
- 2009-07-01 KR KR1020157033151A patent/KR101659530B1/ko not_active Expired - Fee Related
- 2009-07-01 PE PE2009000913A patent/PE20100057A1/es active IP Right Grant
- 2009-07-01 CA CA2730040A patent/CA2730040A1/en not_active Abandoned
- 2009-07-01 PL PL14193392T patent/PL2905014T3/pl unknown
- 2009-07-01 CN CN201410149061.4A patent/CN103976816A/zh active Pending
- 2009-07-01 AR ARP090102452A patent/AR072544A1/es not_active Application Discontinuation
- 2009-07-01 ES ES14193392.9T patent/ES2673154T3/es active Active
- 2009-07-01 JP JP2011515511A patent/JP2011526609A/ja active Pending
- 2009-07-01 KR KR1020117002766A patent/KR20110026516A/ko not_active Ceased
- 2009-07-01 LT LTEP14193392.9T patent/LT2905014T/lt unknown
- 2009-07-01 EP EP09772630.1A patent/EP2313084A4/en not_active Withdrawn
- 2009-07-01 DK DK14193392.9T patent/DK2905014T3/en active
- 2009-07-01 HU HUE14193392A patent/HUE037520T2/hu unknown
- 2009-07-01 TR TR2018/07996T patent/TR201807996T4/tr unknown
- 2009-07-01 US US12/995,905 patent/US20110146693A1/en not_active Abandoned
- 2009-07-01 SI SI200931850T patent/SI2905014T1/en unknown
- 2009-07-01 EP EP14193392.9A patent/EP2905014B1/en active Active
- 2009-07-02 UY UY0001031957A patent/UY31957A/es unknown
-
2013
- 2013-07-03 US US13/934,913 patent/US9999592B2/en active Active
-
2014
- 2014-03-10 JP JP2014045808A patent/JP6008893B2/ja active Active
-
2016
- 2016-06-08 JP JP2016114446A patent/JP2016166245A/ja active Pending
-
2018
- 2018-05-18 US US15/984,310 patent/US10532025B2/en active Active
- 2018-06-04 HR HRP20180869TT patent/HRP20180869T1/hr unknown
- 2018-06-06 CY CY181100595T patent/CY1120878T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072544A1 (es) | Metodo anticonceptivo mejorado. sistema de suministro. uso. progestageno | |
| PE20110573A1 (es) | Sistema de administracion de drogas que contiene progestina | |
| ES2553742T3 (es) | Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina | |
| AR077199A1 (es) | Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| AR065039A1 (es) | Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso | |
| ECSP10010104A (es) | Sistema de administración vaginal | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| AR059174A1 (es) | Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas) | |
| GT201200281A (es) | Formas de dosificación sólidas orales con dosis muy bajas para la hrt | |
| AR064014A1 (es) | Tabletas bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina | |
| DOP2010000253A (es) | Sistema de administracion de drogas con efecto estabilizante | |
| PE20081361A1 (es) | Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas | |
| CR9704A (es) | Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma. | |
| BRPI0713257B8 (pt) | sistema terapêutico transdérmico para a aplicação de norelgestromina | |
| BR112013004455A2 (pt) | composições para fornecimento gástrico de agentes ativos | |
| AR084707A1 (es) | Una composicion farmaceutica de combinacion para tratar enfermedades o condiciones asociados al sistema cardiovascular | |
| UY31343A1 (es) | Composicion con una combinacion de principios activos para el tratamiento del estrenimiento | |
| AR089765A1 (es) | Un sistema para el suministro de un farmaco | |
| CL2009000322A1 (es) | Composicion farmaceutica que comprende flibanserina en su forma amorfa y al menos un excipiente, sistema farmaceutico de liberacion que comprende esta composicion, metodo para fabricar este sistema y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, trastornos del sueño y sexuales, entre otros. | |
| PE20011049A1 (es) | Combinacion de farmacos para el tratamiento de la depresion y trastornos relacionados que comprenden mirtazapina | |
| AR071774A1 (es) | Sal de acetato de un compuesto peptidico que tiene actividad antitumoral y su uso. | |
| AR070375A1 (es) | Sistemas de administracion de drogas que contienen estradiol | |
| AR073086A1 (es) | Composicion farmaceutica para el tratamiento de un trastorno de ansiedad que comprende exo-7-(8-h-8-aza-biciclo(3,2,1)oct-3-iloxi)-cromen-2-ona, uso y equipo | |
| BR112015000647A2 (pt) | composições orais líquidas e pediátricas que contêm nepadutant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |